Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2 study of GSK5864399 in advanced solid tumors
jRCT2031260632Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
01
Overview
Phase 2, open-label trial of GSK5864399 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (2 arms), sponsored by GSK. Primary endpoints: Number of participants with adverse events, Number of participants with dose-limiting toxicities and 8 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
GSK5864399
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260632.